Literature DB >> 25719374

Observations on Prostaglandin Orbitopathy.

Philip L Custer1, Tiffany L Kent.   

Abstract

PURPOSE: To present the various orbital soft-tissue changes that can result from the use of topical prostaglandin analogs.
METHODS: A case series of patients seen in a referral oculoplastic practice with presumed prostaglandin orbitopathy.
RESULTS: Thirty-five patients were found to have a variety of disorders, including deepening of the superior sulci (24/35), hypertrichosis (32/35), periocular erythema (24/35), and meibomian gland dysfunction (18/35). Marginal eyelid thinning with posterior migration of the lash line was commonly present (34/35). Increased eyelid margin tension with horizontal eyelid shortening (32/35) was often associated with lateral canthal deformity or displacement (15/35). Lower eyelid retraction (18/35) seemed to contribute to ptosis in some patients, secondary to apparent tethering at the lateral canthus. Functional conditions resulting from the above structural abnormalities included tractional ptosis (n = 4), cicatricial entropion (n = 3), cicatricial ectropion (n = 2), trichiasis (n = 2), eyelid subluxation (n = 1), and chalazia (n = 1).
CONCLUSIONS: While topical prostaglandin analogs are well-tolerated by many patients with glaucoma, some individuals using these medications develop structural changes of the orbital soft tissue resulting in a variety of cosmetic and functional eyelid disorders. The eyelid margins can thin, causing posterior migration of the lashes. Increased horizontal tension of the eyelids may result in acquired blepharophimosis and upper or lower eyelid malposition. These orbital changes may be partially reversible in some patients. When possible, it is reasonable to withhold the prostaglandin and allow a period of observation before proceeding with surgical correction.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25719374     DOI: 10.1097/IOP.0000000000000431

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  7 in total

1.  In Vivo Effects of Retrobulbar Bimatoprost Injection on Orbital Fat.

Authors:  Kian Eftekhari; M Reza Vagefi; Vivian Lee; James Z Hui; Menglong Zhu; Kimberly Dine; Richard L Anderson; Brigitte Koeberlein; Reas Sulaimankutty; Kenneth S Shindler
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2018 May/Jun       Impact factor: 1.746

2.  Prostaglandin-Associated Periorbital Lipodystrophy in Cosmetic Eyelid Surgery: A Novel Cause of Facial Asymmetry.

Authors:  Kian Eftekhari; Mark D Mifflin; Richard L Anderson
Journal:  Aesthet Surg J       Date:  2015-09-15       Impact factor: 4.283

3.  Influence of Pilocarpine and Timolol on Human Meibomian Gland Epithelial Cells.

Authors:  Yi Zhang; Wendy R Kam; Yang Liu; Xiaomin Chen; David A Sullivan
Journal:  Cornea       Date:  2017-06       Impact factor: 2.651

4.  Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.

Authors:  Xi Han; Yang Liu; Wendy R Kam; David A Sullivan
Journal:  Exp Eye Res       Date:  2018-02-13       Impact factor: 3.467

5.  Periorbital changes associated with prostaglandin analogs in Korean patients.

Authors:  Hee Weon Kim; Youn Joo Choi; Kyung Wha Lee; Min Joung Lee
Journal:  BMC Ophthalmol       Date:  2017-07-17       Impact factor: 2.209

6.  Open-label pilot study to evaluate the effectiveness of topical bimatoprost on rhododendrol-induced refractory leukoderma.

Authors:  Saki Fukaya; Masahiro Kamata; Tomoko Kasanuki; Makoto Yokobori; Shintaro Takeoka; Kotaro Hayashi; Takamitsu Tanaka; Atsuko Fukuyasu; Takeko Ishikawa; Takamitsu Ohnishi; Satoshi Iimuro; Yayoi Tada; Shinichi Watanabe
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

7.  Effect of prostaglandin analogs on matrix metalloproteinases and tissue inhibitor of metalloproteinases in eyelid muscle specimens.

Authors:  Sapir Karli; Juan Alfredo Ayala-Haedo; William J Feuer; Maria Fernandez; Sander Dubovy; Sara T Wester
Journal:  Clin Ophthalmol       Date:  2018-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.